抗逆转录病毒药物与HIV感染者骨折及股骨头坏死风险
基于EuroSIDA大型国际HIV队列,随访11820人共86118人年,评估抗逆转录病毒药物暴露与骨折及股骨头坏死的关系。结果显示曾用或现用替诺福韦二吡呋酯(TDF)与骨折风险升高独立相关,但未发现任何抗逆转录病毒药物与股骨头坏死相关。
要点
- 曾用或现用TDF与骨折风险升高独立相关。
- TDF累积暴露与骨折无关联,其他抗逆转录病毒药物与骨折无关。
- 未发现任何抗逆转录病毒药物与股骨头坏死相关。
核心结论
- 在HIV感染者中,宿主因素、HIV相关变量及合并症影响骨折和股骨头坏死风险。
- TDF暴露是骨折的独立危险因素,但其他抗逆转录病毒药物未显示与骨折相关。
- 未发现任何抗逆转录病毒药物与股骨头坏死相关。
研究设计与样本
- EuroSIDA多中心前瞻性队列研究,纳入11820名HIV感染者,中位年龄41岁,75%男性,中位基线CD4计数440/mm3,70.4%病毒学抑制。
- 随访86118人年,采用泊松回归分析骨折和股骨头坏死的预测因素,评估抗逆转录病毒药物的曾经、当前和累积暴露。
主要发现
- 随访期间发生619例骨折(发病率7.2/1000人年,95%CI 6.6-7.7)和89例股骨头坏死(1.0/1000人年,95%CI 0.8-1.3)。
- 骨折相关因素包括年龄较大、白人种族、较低BMI、静脉吸毒、较低基线CD4、HCV合并感染、既往股骨头坏死、既往骨折、心血管疾病及近12个月内非艾滋病定义癌症。
- 调整后,曾用TDF者骨折发生率升高(1.40;95%CI 1.15-1.70),当前用TDF者亦升高(1.25;95%CI 1.05-1.49)。
- 股骨头坏死风险与白人种族、较低CD4最低值、既往股骨头坏死、既往骨折及既往艾滋病相关,相互调整后无抗逆转录病毒药物与股骨头坏死相关。
临床怎么用
- 对HIV感染者应评估骨折风险,尤其关注TDF暴露史及宿主和合并症因素。
- 处方TDF时需权衡骨折风险,但不应因股骨头坏死风险而调整抗逆转录病毒方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiretrovirals (ARVs) affect bone density and turnover, but their effect on risk of fractures and osteonecrosis of the femoral head is less understood. We investigated if exposure to ARVs increases the risk of both bone outcomes. METHODS: EuroSIDA participants were followed to assess fractures and osteonecrosis. Poisson regression identified clinical, laboratory and demographic predictors of either bone outcome. Ever, current, and cumulative exposures to ARVs were assessed. RESULTS: During 86118 PYFU among 11820 included persons (median age 41y, 75% male, median baseline CD4 440/mm3, 70.4% virologically suppressed), there were 619 fractures (incidence/1000 PYFU 7.2; 95% CI 6.6-7.7) and 89 osteonecrosis (1.0; 0.8-1.3). Older age, white race, lower BMI, IV drug use, lower baseline CD4, HCV coinfection, prior osteonecrosis, prior fracture, cardiovascular disease, and recent non-AIDS cancer (last 12 months) were associated with fractures. After adjustment, persons who had ever used tenofovir disoproxil fumarate (TDF) (1.40; 1.15-1.70) or who were currently on TDF (1.25; 1.05-1.49) had higher incidence of fractures. There was no association between cumulative exposure to TDF and fractures (1.08/5 y exposure; 0.94-1.25). No other ARV was associated with fractures (all P > .1). Risk of osteonecrosis was associated with white race, lower nadir CD4, prior osteonecrosis, prior fracture, and prior AIDS. After mutual adjustment, no ARV was associated with osteonecrosis. CONCLUSIONS: In human immunodeficiency virus (HIV) infection, host factors, HIV-specific variables, and comorbidities contribute to risk of fractures and osteonecrosis. Exposure to TDF, but not other ARVs, was an independent risk factor for fractures.
引用
- Borges ÁH, Hoy J, Florence E, et al. Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. Clin Infect Dis. 2017. PMID: 28329090. doi:10.1093/cid/cix167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。